Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Osteoporosis

  Free Subscription


12.06.2017

3 J Clin Endocrinol Metab
9 Osteoporos Int
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    J Clin Endocrinol Metab

  1. SCHORR M, Marengi DA, Pulumo R, Yu E, et al
    Oxytocin and its relationship to body composition, bone mineral density and hip geometry across the weight spectrum
    J Clin Endocrinol Metab. 2017 May 10. doi: 10.1210/jc.2016-3963.
    PubMed     Text format     Abstract available

  2. LAMY O, Gonzalez-Rodriguez E, Aubry-Rozier B
    Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation.
    J Clin Endocrinol Metab. 2017;102:2112.
    PubMed     Text format    

  3. RAO SD, Qiu S, Dhaliwal R, Bhadada SK, et al
    Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation.
    J Clin Endocrinol Metab. 2017;102:2111.
    PubMed     Text format    


    Osteoporos Int

  4. SHAH VN, Harrall KK, Shah CS, Gallo TL, et al
    Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature.
    Osteoporos Int. 2017 Jun 3. doi: 10.1007/s00198-017-4097.
    PubMed     Text format     Abstract available

  5. GIFRE L, Ruiz-Gaspa S, Carrasco JL, Portell E, et al
    Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Osteoporos Int. 2017 Jun 4. doi: 10.1007/s00198-017-4090.
    PubMed     Text format     Abstract available

  6. COULSON J, Bagley L, Barnouin Y, Bradburn S, et al
    Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
    Osteoporos Int. 2017 Jun 5. doi: 10.1007/s00198-017-4104.
    PubMed     Text format     Abstract available

  7. SHIEK AHMAD B, Petty SJ, Gorelik A, O'Brien TJ, et al
    Bone loss with antiepileptic drug therapy: a twin and sibling study.
    Osteoporos Int. 2017 Jun 6. doi: 10.1007/s00198-017-4098.
    PubMed     Text format     Abstract available

  8. LEHMANN T, Aeberli D
    Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
    Osteoporos Int. 2017 Jun 6. doi: 10.1007/s00198-017-4108.
    PubMed     Text format    

  9. BLANCO E, Burrows R, Reyes M, Lozoff B, et al
    Breastfeeding as the sole source of milk for 6 months and adolescent bone mineral density.
    Osteoporos Int. 2017 Jun 6. doi: 10.1007/s00198-017-4106.
    PubMed     Text format     Abstract available

  10. WRIGHT NC, Foster PJ, Mudano AS, Melnick JA, et al
    Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.
    Osteoporos Int. 2017 Jun 7. doi: 10.1007/s00198-017-4105.
    PubMed     Text format    

  11. SVENSSON HK, Olsson L-, Hansson T, Karlsson J, et al
    The effects of person-centered or other supportive interventions in older women with osteoporotic vertebral compression fractures-a systematic review of the literature.
    Osteoporos Int. 2017 Jun 6. doi: 10.1007/s00198-017-4099.
    PubMed     Text format     Abstract available

  12. WEYCKER D, Edelsberg J, Barron R, Atwood M, et al
    Predictors of near-term fracture in osteoporotic women aged >/=65 years, based on data from the study of osteoporotic fractures.
    Osteoporos Int. 2017 Jun 7. doi: 10.1007/s00198-017-4103.
    PubMed     Text format     Abstract available


    PLoS One

  13. XU F, Huang M, Jin Y, Kong Q, et al
    Moxibustion treatment for primary osteoporosis: A systematic review of randomized controlled trials.
    PLoS One. 2017;12:e0178688.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: